Trial Profile

Phase II study of seliciclib in patients with previously treated advanced nasopharyngeal cancer.

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 11 Jun 2009

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Seliciclib (Primary)
Indications Nasopharyngeal cancer; Solid tumours
Focus Adverse reactions; Therapeutic Use
Sponsors Cyclacel Pharmaceuticals

Most Recent Events

29 May 2009 Safety results from 23 patients in the lead-in part of the study have been reported at ASCO 2009. The trial will now proceed into the second part of the study; reported in a Cyclacel media release.
08 Nov 2007 Recruitment is expected to start by the end of 2007.
08 Feb 2007 New trial record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com